Literature DB >> 9278194

Enantioselective pharmacokinetics of mefloquine during long-term intake of the prophylactic dose.

U Hellgren1, I Berggren-Palme, Y Bergqvist, M Jerling.   

Abstract

AIMS: To investigate the kinetics of the (+)RS- and (-)SR-enantiomers and the carboxylic acid metabolite (MMQ) of the antimalarial drug mefloquine (MQ) in healthy volunteers.
METHODS: Ten subjects of which three were poor metabolizers of debrisoquine received racemic MQ 250 mg once weekly for 16 weeks. The kinetics were followed in plasma and urine and evaluated by individual kinetic modelling as well as by a nonparametric population kinetic method.
RESULTS: A two-compartment model adequately described the disposition of (+)RS-MQ. CL/F was 6.5 +/- 1.8 l h(-1), V(ss)/F 815 +/- 165 l, and k 0.0081 +/- 0.0023 h(-1). The kinetics of (-)SR-MQ were time- and/or concentration dependent with a lower oral clearance (0.92 +/- 0.25 vs 2.14 +/- 0.63 l h(-1), 95% CI for the difference 0.86-1.60 l h(-1)) and a longer half-life (345 vs 185 h, 95% CI for the difference 47-291 h) after the last dose compared with the first dose. Clearance of (+)RS-MQ and (-)SR-MQ was significantly correlated within subjects (r = 0.69, P < 0.05). Urinary recovery of unchanged substance was 8.7% for (+)RS-MQ and 12.3% for (-)SR-MQ. The elimination of MMQ was disposition rate-limited and not determined by its rate of formation. Poor metabolizers of debrisoquine did not differ from extensive metabolizers in the kinetics of any compound.
CONCLUSIONS: The MQ enantiomers differ extensively in their disposition both with regard to parameter values and the kinetic stability over time during repeated dosing with racemic MQ. Kinetic modelling of racemic MQ is therefore inadequate.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9278194      PMCID: PMC2042812          DOI: 10.1046/j.1365-2125.1997.00633.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  7 in total

Review 1.  Pharmacokinetic interactions of antimalarial agents.

Authors:  P T Giao; P J de Vries
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

2.  Pharmacokinetic interaction between mefloquine and ritonavir in healthy volunteers.

Authors:  Y Khaliq; K Gallicano; C Tisdale; G Carignan; C Cooper; A McCarthy
Journal:  Br J Clin Pharmacol       Date:  2001-06       Impact factor: 4.335

3.  Population Pharmacokinetics of Mefloquine Intermittent Preventive Treatment for Malaria in Pregnancy in Gabon.

Authors:  Michael Ramharter; Matthias Schwab; Clara Menendez; Reinhold Kerb; Thorsten Lehr; Ghyslain Mombo-Ngoma; Rella Zoleko Manego; Daisy Akerey-Diop; Arti Basra; Jean-Rodolphe Mackanga; Heike Würbel; Jan-Georg Wojtyniak; Raquel Gonzalez; Ute Hofmann; Mirjam Geditz; Pierre-Blaise Matsiegui; Peter G Kremsner
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

Review 4.  Stereoselectivity in the pharmacodynamics and pharmacokinetics of the chiral antimalarial drugs.

Authors:  Dion R Brocks; Reza Mehvar
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

5.  Mefloquine induces dose-related neurological effects in a rat model.

Authors:  G Dow; R Bauman; D Caridha; M Cabezas; F Du; R Gomez-Lobo; M Park; K Smith; K Cannard
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

6.  Cerebral uptake of mefloquine enantiomers with and without the P-gp inhibitor elacridar (GF1210918) in mice.

Authors:  Sylvie Barraud de Lagerie; Emmanuelle Comets; Céline Gautrand; Christine Fernandez; Daniel Auchere; Eric Singlas; France Mentre; François Gimenez
Journal:  Br J Pharmacol       Date:  2004-03-15       Impact factor: 8.739

Review 7.  The position of mefloquine as a 21st century malaria chemoprophylaxis.

Authors:  Patricia Schlagenhauf; Miriam Adamcova; Loredana Regep; Martin T Schaerer; Hans-Georg Rhein
Journal:  Malar J       Date:  2010-12-09       Impact factor: 2.979

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.